We have investigated in vitro the release kinetics and bioactivity of fibroblast growth factor-2 (FGF-2) released from a carrier of fibrin sealant. In order to evaluate the effects of the FGF-2 delivery mechanism on the repair of articular cartilage, full-thickness cylindrical defects, 5 mm in diameter and 4 mm in depth, which were too large to undergo spontaneous repair, were created in the femoral trochlea of rabbit knees. These defects were then filled with the sealant.
We have investigated in vitro the release kinetics and bioactivity of fibroblast growth factor-2 (FGF-2) released from a carrier of fibrin sealant. In order to evaluate the effects of the FGF-2 delivery mechanism on the repair of articular cartilage, full-thickness cylindrical defects, 5 mm in diameter and 4 mm in depth, which were too large to undergo spontaneous repair, were created in the femoral trochlea of rabbit knees. These defects were then filled with the sealant.
Approximately 50% of the FGF-2 was released from the sealant within 24 hours while its original bioactivity was maintained. The implantation of the fibrin sealant incorporating FGF-2 successfully induced healing of the surface with hyaline cartilage and concomitant repair of the subchondral bone at eight weeks after the creation of the defect.
Our findings suggest that this delivery method for FGF-2 may be useful for promoting regenerative repair of full-thickness defects of articular cartilage in humans.
Articular cartilage has a very limited capacity for repair. Clinical procedures, such as stimulation of marrow by microfracture, mosaicplasty and autologous chondrocyte implantation have not always provided satisfactory results, and repair of articular cartilage remains an unsolved clinical problem. 1 Full-thickness defects which penetrate the subchondral bone produce marrow-derived mesenchymal cell-induced repair responses, 2 although these tend to result in the generation of either fibrous or fibrocartilaginous tissue and only produce hyaline cartilage to a very limited extent. Analyses of skeletal development in embryos and chondrogenic cell lines in culture have implicated a variety of signalling molecules as critical regulatory factors for the sequence of events during chondrogenesis. 3, 4 Based on these findings, attempts have been made to promote the regenerative repair of full-thickness defects by activating marrowderived mesenchymal cells using growth and differentiation signals. 5 In previous studies, [6] [7] [8] fibroblast growth factor-2 (FGF-2) has been shown to be involved in the repair process of full-thickness articular cartilage defects in rabbits. The continuous administration of a neutralising monoclonal antibody against FGF-2 (bFM-1) interrupted chondrogenic repair in defects 3 mm in diameter, which would otherwise have repaired spontaneously. By contrast, administration of FGF-2 for two weeks after the creation of defects of 5 mm in diameter, which were too large to repair spontaneously, induced regenerative repair of the articular cartilage and subchondral bone. Additionally, the continuous administration of FGF-2 for one day was sufficient for the induction of the chondrogenic repair response. 9 Assessment of undifferentiated cell proliferation and in vitro migration assays have indicated that FGF-2 promotes the mobilisation and recruitment of actively replicating undifferentiated mesenchymal cells into the defects from the bone marrow, and subsequently induces regenerative repair of articular cartilage in full-thickness defects. 8, 9 Bioactive peptides such as FGF-2 rapidly disperse from their sites of application when applied in vivo. 9, 10 In one study, FGF-2 injected into blood clots filling defects of the articular cartilage in a rabbit model led to the clearance of more than 50% of the FGF-2 from the defect within 30 minutes. 9 Therefore an FGF-2-controlled release system which allows the local delivery and retention of FGF-2 at the site of implantation is desired for clinical application.
It is important that such a growth-factor controlled-release system maintains the original biological activity of the growth factor and enhances tissue-repair processes at the site of implantation. 11 We have therefore tested the suitability of a fibrin sealant as a controlledrelease carrier of FGF-2.
Preparation of FGF-2-incorporating fibrin clots. We used Bolheal (Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan), a commercially available fibrin sealant prepared with the Blanova virus removal filter (Asahi Kasei Corporation, Tokyo, Japan), to prevent virus and prion contamination. A solution containing 80 mg of fibrinogen and 75 µ of fibrin-stabilising factor XIII was prepared with 1 ml of the plasmin inhibitor aprotinin (1000 KIU/ml). Thrombin (250 IU) was dissolved in 1 ml of calcium chloride solution (2.95 mg/ml), and lyophilised FGF-2 (Fiblast; Kaken Pharmaceutical Co, Tokyo, Japan) in phosphate-buffered saline (PBS; pH 7.4) containing 0.5% bovine serum albumin to prepare solutions of FGF-2 of various concentrations as required. Each FGF-2 solution was diluted by 100-fold by the addition of the prepared fibrinogen solution to which the thrombin solution was added at a ratio of 1:1 (v/v) to prepare FGF-2-incorporating fibrin clots. In vitro analysis of FGF-2 release kinetics. Aliquots of 100 µl of the fibrinogen solution containing FGF-2 were mixed with the thrombin solution in order to prepare FGF-2-incorporating fibrin clots containing 1 µg of FGF-2. A total of 42 FGF-2-incoporating fibrin clots were individually placed in 1 ml of PBS (pH 7.4) containing 0.5% bovine serum albumin, and were incubated at 37˚C for 1, 6, 24, 48, 72, 96 and 120 hours (six were used for each time point). At each time point, basal media samples were collected from the FGF-2-incorporating fibrin clots, and immediately frozen for storage at -80˚C until analysis. The amounts of FGF-2 in the media samples were quantified using an enzyme-linked immunosorbent assay (ELISA) kit (Quantikine Immunoassay kit DFB50; R&D Systems, Minneapolis, Minnesota) according to the manufacturer's instructions, except that the standard curves were prepared with the same FGF-2 used in the experiments. The percentage of released FGF-2 at each time point was determined as the ratio of the amount of FGF-2 in 1 ml of the sample, which was calculated by reference to the standard curve, relative to the original amount (1 µg) in the FGF-2-incorporating fibrin clots. In vitro analysis of FGF-2 bioactivity. Aliquots of 100 µl of the fibrinogen solution containing FGF-2 were mixed with the thrombin solution to prepare FGF-2-incorporating fibrin clots containing 20 ng of FGF-2. A total of six FGF-2-incorporating fibrin clots were individually placed in 2 ml of PBS (pH 7.4) containing 0.5% bovine serum albumin and incubated at 37˚C for 24 hours. Next, basal media samples were collected from the FGF-2-incorporating fibrin clots, and immediately frozen for storage at -80˚C. Balb/ c3T3 mouse embryo fibroblasts (clone A31; RIKEN Cell Bank, Tsukuba, Japan) were subcultured and used for determination of the activity of the growth factor as previously described 12 with some modifications. Briefly, 1 × 10 5 cells in 5 ml of Dulbecco's modified Eagle's medium (DMEM; Invitrogen Corporation, Carlsbad, California) containing 10% calf serum (Invitrogen Corporation) and antibiotics (100 U/ml of penicillin G, 100 µg/ml of streptomycin and 0.25 µg/ml of amphotericin B; Invitrogen Corporation) were seeded into 25 cm 2 culture flasks and cultured at 37˚C in a humidified atmosphere of 5% CO 2 . Confluent cells grown in 10% calf serum underwent trypsin digestion and were collected by centrifugation, resuspended in medium and replated at 5 × 10 4 cells/flask in 4 ml of medium containing 5% calf serum in a total of 18 flasks. After 24 hours, the medium was removed and the cells were washed twice with serum-free DMEM, before 4 ml of medium containing 0.6% calf serum were added. After another 24 hours, 1 ml aliquots of six basal media samples, which were thawed after storage at -80˚C as described above, were respectively transferred into six of the cell-culture flasks (fibrin sealant (FS)/FGF-2 group). Meanwhile, 1 ml of FGF-2 solution (5 ng/ml) was added to another six flasks (FGF-2 group). The remaining six flasks received 1 ml of PBS (PBS group). After incubation for 48 hours, the number of cells in each flask was counted using a haemocytometer after trypsin digestion. The stimulation ratios of the proliferative responses of the cells in the FS/ FGF-2 and FGF-2 groups were calculated as the number of cells after incubation for 48 hours divided by the number of cells in the PBS group after incubation for 48 hours. Experimental procedures. We used adolescent male Japanese white rabbits aged between 15 and 16 weeks and weighing 3.0 kg to 3.4 kg (KBT Oriental Co Ltd, Tosu, Japan). They were housed individually and all animal care and experimental procedures were conducted in accordance with our institutional guidelines. A total of 36 rabbits were anaesthetised by intravenous administration of sodium thiopentone (30 mg/kg body-weight). The right knee was approached through a medial parapatellar incision under sterile conditions, and the patella dislocated laterally. Full-thickness cylindrical defects of 5 mm in diameter and 4 mm depth were created in the centre of the femoral trochlea of one knee using a hand drill equipped with a 5 mm diameter drill-bit as described previously. 6 We prepared 1 ml aliquots of fibrinogen solutions containing 18.3 ng, 183 ng, 917 ng and 1834 ng of FGF-2. The defects were thoroughly washed with sterile saline, and the fibrinogen solutions containing the various amounts of FGF-2 and the same volume of thrombin solution were simultaneously injected into the defects of 24 animals, six rabbits for each amount of FGF-2 administered, until the defect was completely filled, using a double-syringe applicator (FS/FGF-2 group). In another six animals, the fibrinogen solutions without FGF-2 and the same volume of thrombin solution were simultaneously injected into the defects (FS group). At approximately one minute after the injection, the FGF-2-incorporating fibrin sealant and fibrin sealant without FGF-2 formed gels and adhered to the defects. After reduction of the patella, the knee was flexed and extended several times to confirm the stability of the fibrin clots in the defects. In the remaining six animals, the defects were left untreated (control group). The articular capsule and skin were independently closed with 5-0 nylon sutures. All the animals were allowed to walk freely without any splints. Histological and immunohistochemical analyses. All the animals were killed with an overdose of sodium thiopentone at eight weeks after the creation of the defect. The distal portion of each femur was fixed in 4% paraformaldehyde at room temperature for one hour, decalcified in 10% ethylenedianinetetraacetic acid (EDTA) for three weeks and embedded in paraffin for subsequent histological analysis. Transverse sections (5 µm thick) were cut and stained with Safranin-O. For semiquantitative analysis of the reparative tissues, the sections were examined in a blinded manner by two observers (II, SK) who were unaware of the group assignment, and scored according to the histological grading scale of Pineda et al, 13 with some modifications (Table I) . Briefly, the scale used was inversely correlated to the original scale, such that better recovery of the articular structure had a higher score.
The presence of type-II collagen in the repair tissues was examined immunohistochemically. Briefly, paraffin-embedded sections were deparaffinised and rehydrated. Endogenous peroxide activity was blocked with 0.5% hydrogen peroxide in methanol, followed by washing with 0.1% bovine serum albumin in Tris-buffered saline. Next, the sections were treated with 500 U/ml of testicular hyaluronidase (Sigma Chemical Co, St Louis, Missouri), followed by reduction of non-specific staining by incubation with horse serum. The sections were incubated overnight at 4˚C, with a mouse monoclonal antibody against human type-II collagen at a dilution of 1:100 (Fuji Chemical, Takaoka, Japan) which specifically cross-reacted with rabbit type-II collagen. Finally, the samples were treated with the Vectastain avidin-biotin-peroxidase complex (ABC) kit (Vector Laboratories, Burlingame, California), reacted with diaminobenzidine solution and counterstained with haematoxylin. Statistical analysis. This was performed for the release ratios of FGF-2 and the stimulation ratios of the proliferative responses of Balb/c3T3 fibroblasts using the KruskalWallis test and Fisher's post hoc test. One-way ANOVA followed by Tukey-Kramer 14 honestly significant difference was used for the histological scores of the repair tissues in the 5 mm diameter defects. A p-value of less than 0.05 was considered to be significant. All statistical analyses were performed using JMP version 5.1.2 (SAS Institute Inc., Cary, North Carolina).
Results
Time course of FGF-2 release from FGF-2-incorporating fibrin clots. The mean release ratio of FGF-2 from the FGF-2-incorporating fibrin clots increased over the following time course: 2.7 ± 0.5% after one hour, 10.5 ± 1.5% after six hours, 50.1 ± 5.0% after 24 hours, 63.0 ± 5.0% after 48 hours and 72.0 ± 7.0% after 72 hours. At each interval up to 72 hours, there was a significant increase in the release of FGF-2. Beyond 72 hours the amount of FGF-2 in the basal media did not increase significantly (Fig. 1) . Proliferative responses of Balb/c3T3 fibroblasts. The mean amount of FGF-2 in a 2 ml medium sample obtained after incubating an FGF-2-incorporating fibrin clot containing 20 ng of FGF-2 for 24 hours was estimated to be 10 ng. Hence, it was assumed that 1 ml of the medium sample, which was collected, stored at -80˚C and then thawed, contained 5 ng of FGF-2. Therefore, an FGF-2 solution of 5 ng/ml (1 ml), which was considered to have equal bioactivity to the medium sample (1 ml), was added to the culture medium of the FGF-2 group, and the bioactivity of the FGF-2 released from the FGF-2-incorporating fibrin clots was investigated by comparing the stimulatory effect of the FGF-2 solution (5 ng/ml) on cell proliferation with that of the media samples.
After 48 hours of incubation, the stimulation ratio of the proliferative responses of cells relative to the PBS group in the FS/FGF-2 group was a mean of 1.9 ± 0.2, while that of the proliferative responses of cells in the FGF-2 group was a mean of 2.14 ± 0.1. There was no significant difference between the stimulation ratios of the proliferative responses of the cells between the FS/FGF-2 and FGF-2 groups (Fisher's post hoc test p = 0.1144; Fig. 2) suggesting that the presence of the fibrin did not impair the activity of the FGF-2, while the stimulation ratios of the FS/FGF-2 
Effect of FGF-2-incorporating fibrin clots on the repair responses of 5 mm diameter full-thickness defects.
In a previous study, 9 administration of FGF-2 successfully produced regenerative repair of 5 mm diameter defects in articular cartilage using an osmotic pump filled with a 300 ng/ml solution of FDF-2 delivered at a rate of 0.5 µl for 24 hours. The amount of FGF-2 administered into the joint cavity under these conditions was calculated to be approximately 3.6 ng. Therefore the FGF-2-incorporating fibrin sealants filling the 5 mm diameter defects needed to contain 7.2 ng of FGF-2 in order to release 3.6 ng of FGF-2 into the defects within 24 hours. The volume of the 5 mm diameter cylindrical defects was calculated to be approximately 78.5 µl. Therefore 1 ml of fibrinogen solutions containing 183 ng of FGF-2 were prepared equating to 7.2 ng of FGF-2. Furthermore, the effects of FGF-2-incorporating fibrin sealants containing one-tenth, and five and ten times the amount of FGF-2 on the repair of the defects of the articular cartilage were investigated.
In the control group, the defects were covered with fibrous tissue alone, although the subchondral bone was almost fully reconstituted. The cells covering the defects were mostly non-chondrocytic and the matrix was not stained by Safranin-O (Fig. 3a) . Similar results were obtained for the FS group. The filling of the defects with fibrous tissue in the FS group was less complete than that in the control group (Fig. 3b) . The results for the FS/FGF-2 group containing 0.72 ng of FGF-2 were similar to those for the FS group (Fig. 3c) . By contrast, the defects in the FS/FGF-2 group containing 7.2 ng of FGF-2 had cartilaginous tissue which was well stained with Safranin-O covering the articular surface with reconstruction of the subchondral bone up to the original bone-articular cartilage junction (Fig. 3d) . Similar results were observed in the FS/FGF-2 groups containing 36 ng and 72 ng of FGF-2 (Figs 3e and 3f) . The matrix staining of the surface of the cartilaginous tissue in the defects tended to be more distinct with increasing amounts of FGF-2 (Figs 3d, 3e and 3f).
In the control group and the FS and FS/FGF-2 groups containing 0.72 ng of FGF-2, type-II collagen immunoreactivity was detected in the pre-existing articular cartilage, but not in the fibrous tissue covering the surface of the defects. In the FS/FGF-2 groups containing 7.2 ng, 36 ng and 72 ng of FGF-2, the regenerated cartilaginous tissues showed marked expressions of type-II collagen to extents comparable with that in the pre-existing articular cartilage (Fig. 4) .
The mean histological scores in the FS/FGF-2 groups containing 0.72 ng, 7.2 ng, 36 ng and 72 ng of FGF-2 were 4.9 ± 1.8, 11.0 ± 0.9, 11.5 ± 0.5 and 117 ± 0.5, respectively. The scores of the repair tissues in the FS/FGF-2 subgroups in which the fibrin clots in the defects incorporated ≥ 7.2 ng of FGF-2 were significantly higher than those of the control (mean 5.2 ± 2.1) and FS (mean 4.6 ± 1.3) groups. There was no statistical difference between the scores of the control and FS groups (ANOVA, p = 0.2246) (Table II) .
Discussion
Our study has produced the following three findings. First, FGF-2-incorporating fibrin clots can release FGF-2 in a wellcontrolled manner. Secondly, the FGF-2 released from the FGF-2-incorporating fibrin clots retains the original FGF-2 bioactivity and lastly, regeneration of the surface articular cartilage with concomitant repair of the subchondral bone is induced by implantation of FGF-2-incorporating fibrin clots into full-thickness defects 5 mm in diameter in rabbits. These findings indicate that an FGF-2-incorporating fibrin sealant can be useful for the regenerative repair of articular cartilage in rabbits. In our study, as in a previous animal study, 15 we set the sample size at six animals to test the reliability for statistical significance. The results revealed that the minimum sample size, giving 80% power, was nine when six groups were compared using a non-parametric test. However, a FGF-2-incorporating fibrin clot containing 0.72 ng of FGF-2 could not induce the regenerative repair of cartilage in a 5 mm diameter full-thickness defect, which was in accord with our previous data. 6 Therefore it was thought reasonable to categorise the six groups into two; i.e. an experimental FS/ FGF-2 group (FGF-2: 7.2 ng, 36 ng and 72 ng) and a control group (untreated, FS only, FGF-2: 0.72 ng). Between the two groups, a significant difference was found in both parametric (p < 0.0001) and non-parametric tests (p < 0.0001) , with the statistical power being > 95%.
The molecular and physiological characteristics of FGF-2, 16, 17 such as its polyionic complexion with carrier materials and binding capacity with heparin, have been used to develop controlled-release systems for FGF-2. It is positively charged at neutral pH, since it contains basic amino-acid residues, such as lysine and arginine, in both its N-and C-termini. Tabata and Ikada 18 used acidic gelatin as a carrier of FGF-2 based on its polyionic complexion with the gelatin material, which is negatively charged at neutral pH. However, FGF-2 is also a heparin-binding growth factor, and its binding capacity for heparin occurs through the previously described basic amino-acid residues, as well as 2-O-or N-linked sulphate groups. Liu et al 19 used a hyaluronate-heparin conjugate gel as a carrier for FGF-2 based on the heparin-binding capacity of FGF-2. In our study, FGF-2 was added to a fibrinogen solution followed by mixing with a thrombin solution to create FGF-2-incorporating fibrin clots. Sahni, Odrljin and Francis 20 showed that FGF-2 has binding capacities for fibrin and fibrinogen in a protein-binding study using radio-isotopes. In a more recent study using an FGF-2 mutagenesis tech- nique, the same group showed that five residues within FGF-2, namely Phe95, Ser100, Assn102, Arg107 and Arg109, are binding sites for fibrinogen. 21 In our study, FGF-2-incorporating fibrin clots released approximately 50% of the initial FGF-2 dose by 24 hours. By contrast, Sakiyama-Elbert and Hubbell 22 reported that the release of FGF-2 from a fibrin matrix containing heparin immobilised by a bi-domain peptide was approximately 0.1% of the initial FGF-2 dose over 30 days. This difference in the release kinetics of FGF-2 is considered to be caused by the differing binding strengths between FGF-2 and the carrier materials.
Denaturation and inactivation of growth factors occur due to the effects of heat, proteases and acidic conditions. FGF-2 rapidly loses its biological activity after exposure to heat at temperatures above 50˚C or after treatment with trypsin. The activity of FGF-2 almost completely disappears after exposure to pH < 3, although it is stable between pH 5 and pH 7. 23 In our study, the fibrinogen and thrombin solutions were adjusted to be approximately 37˚C before use, and there were no proteases among the components of the fibrin sealant used. Furthermore, the pH values of the fibrinogen and thrombin solutions were 6.0 to 7.3 and 6.5 to 7.5, respectively. Taking these points into consideration, the FGF-2 bio-activity assays indexed by the proliferative capacity of Balb/c3T3 fibroblasts demonstrated that the FGF-2 released from FGF-2-incorporating fibrin clots maintained its original biological activity.
It has been reported that autologous fibrin promotes the repair of musculoskeletal tissues. [24] [25] [26] [27] Implantation of autologous fibrin clots into full-thickness defects of articular cartilage increases the number of repair cells in the defects at early stages after the creation of the defect and subsequently leads to more uniform and organised repair tissues in the defects compared with untreated defects. [25] [26] [27] These positive effects on tissue repair are considered to depend not only on the function of the fibrin strands as a scaffold for the cells, 28 but also on the effects of various growth factors. 29 By contrast, in a study by Brittberg et al 30 in which full-thickness osteochondral defects were filled with the fibrin sealant Tisseel, no invasion by repair cells of the fibrin sealant occupying the defects was observed eight days after the creation of the defect, and the subsequent repair tissues were inferior to those in untreated defects. These authors also reported a lack of ingrowth of cultured chondrocytes into their fibrin sealant clots, although such ingrowth was observed in homologous fibrin clots. They therefore concluded that their fibrin sealant did not contain any of the growth factors which regulate the migration of cells into fibrin clots and are present in autologous fibrin, such that the repair of osteochondral defects was impeded by the implantation of fibrin sealant. In agreement with their results, we have shown that articular cartilage was not regenerated after implantation of our fibrin sealant alone, and that the repair of defects in the FS group was worse than that in the untreated control group, although there was no statistical difference between the groups. Using a porcine full-thickness incisional cutaneous wound model, Petratos et al 31 compared the repair tissues of wounds filled by a fibrin sealant with those of wounds filled by a fibrin sealant containing transforming growth factor (TGF)-β2, which can promote the migration of mesenchymal cells. 32 Seven days after the creation of the wound, the FS/TGF-β2-treated wounds showed infiltration of fibroblasts into the fibrin sealant, whereas the FS-treated wounds did not. As a consequence, the tensile strength of the repair tissues of wounds sealed with the fibrin sealant containing TGF-β2 was enhanced at 14 days after the creation of the wound compared with that of wounds sealed with the fibrin sealant alone. In our study, regenerative repair of cartilage was induced in the FGF-2-incorporating fibrin-sealantimplanted defects. These results are considered to depend on the effects of FGF-2 on the migration of marrow-derived mesenchymal cells in rabbits, demonstrated by Boyden chamber assays in a previous study. 9 Fibrin sealants can be used as controlled-release carriers of antibiotics or anti-tumour drugs, 33, 34 and are already used clinically. Our study has shown that a fibrin sealant also shows potential as a controlled-release carrier of FGF-2. Fibrin sealants have already been used in joint surgery procedures such as repair of osteochondral injury and autologous chondrocyte implantation. 35, 36 They form gels after local mixing of fibrinogen and thrombin solutions and can easily adapt to osteochondral defects with uniform or complicated shapes. Furthermore, the bond strength of fibrin sealants is of the order of 0.01 MPa. 37 Kaplonyi et al 35 reported that no displacement or separation of the fragment occurred in 21 patients with a chondral or osteochondral detachment fixed using a fibrin sealant alone. In our Immunohistochemistry for type-II collagen in the repair tissues of a 5 mm diameter defect treated with a fibrin sealant containing 7.2 ng of fibroblast growth factor-2 (FGF-2) at eight weeks after the creation of the defect. The arrowheads indicate the boundary between the preexisting articular cartilage and the repair tissues (haematoxylin; bar, 500 µm).
study, a fibrin sealant with or without FGF-2 injected into defects rapidly formed a gel, adhered to the defects and was not displaced even after flexion and extension of the knee after reduction of the patella. Fibrin sealants can be used in arthroscopic surgery because the fibrinogen and thrombin solutions can be administered locally using a simultaneous syringe applicator. 36 Because of these advantages, FGF-2-incorporating fibrin sealants may prove to be useful as a controlled-release system for FGF-2 for the regenerative repair of full-thickness defects of articular cartilage in humans.
